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Highlights 19 
 We collected race performance data for National Hunt racehorses treated for superficial 20 
digital flexor tendonitis. 21 
 We compared racing performance for 5 common treatment modalities in treated and age- and 22 
sex-matched control horses. 23 
 Our data demonstrate that SDF tendonitis remains a career limiting injury. 24 
 Control horses raced more often, with higher performance rating and a longer racing distance, 25 
after the date of case injury. 26 
 Rate of return to racing was not associated with lesion severity or treatment group. 27 
 28 
Abstract 29 
Superficial digital flexor (SDF) tendonitis is a common injury in Thoroughbred 30 
racehorses. Injuries require prolonged rehabilitation, with unpredictable outcomes and a high 31 
incidence of re-injury. This observational case-control study aimed to compare race outcomes 32 
after commonly advocated treatments for tendon healing. Clinical and racing records were 33 
evaluated for 127 National Hunt racehorses treated between 2007 and 2011 for an SDF 34 
tendon injury. Two age- and sex-matched control horses were selected for each case horse to 35 
analyse the effect on post-injury racing outcomes of pre-injury data, lesion severity and 36 
treatment group (controlled exercise alone, bar firing, intralesional platelet-rich plasma 37 
(PRP), tendon splitting, tendon splitting combined with bar firing). 38 
 39 
 Control horses raced more often than case horses, with higher maximum racing post 40 
rating (RPRmax) and longer racing distances. Pre-injury racing performance was not 41 
associated with treatment group. Rate of return to racing was not associated with lesion 42 
severity or treatment group. Number of races, total distance raced post-injury and RPRmax 43 
were not associated with lesion severity or treatment group. Controlled exercise alone offered 44 
similar post-injury racing outcomes in National Hunt racehorses with SDF tendonitis to the 45 
other treatment options examined. Bar firing, either alone or in conjunction with tendon 46 
splitting, provided no additional benefit in rate of return to racing and race performance. 47 
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Introduction 51 
Superficial digital flexor (SDF) tendonitis is the most common cause of lameness in 52 
National Hunt racehorses, with prevalences as high as 24% (Lam et al., 2007; Avella et al., 53 
2009; Dyson et al., 2011), or 1.71 per 100 horse months in training (Ely et al., 2009).  SDF 54 
injuries require prolonged rehabilitation, with unpredictable outcomes and high incidences of 55 
re-injury (Marr et al., 1993; O'Meara et al., 2010). SDF tendonitis is often career ending 56 
(Marr et al., 1993; Lam et al., 2007; Dyson et al., 2011). 57 
 58 
Immediate treatment of SDF tendonitis targets a reduction in inflammation (Ross et 59 
al., 2011; Avella and Smith, 2012), and thereafter various interventions are advocated to 60 
improve tendon healing. Tendon firing and blistering were believed to promote repair but 61 
positive clinical evidence is lacking and these treatments are widely considered unethical
1
 62 
(Silver et al., 1983; Marr and Bowen, 2012). Tendon splitting to release the pressure of 63 
haemorrhage and promote vascularisation in the injured area has yielded mixed results 64 
(Stromberg.B et al., 1974; Henninger et al., 1990; Ross et al., 2011). Desmotomy of the 65 
accessory ligament of the superficial digital flexor tendon produced favourable rates of return 66 
to racing and number of races completed but resulted in increased suspensory ligament strain 67 
experimentally and higher incidence of suspensory ligament desmitis clinically (Bramlage, 68 
1986; Bramlage, 2012). Intralesional β-aminopropionitrile fumerate, polysulphated 69 
glycosaminoglycans and sodium hyaluronate (Dowling et al., 2000) have been superceded by 70 
regenerative therapies. Isolated exogenous growth factors such as insulin-like growth factor 1 71 
and transforming growth factor-β can be administered intra-lesionally (Dowling et al., 2000; 72 
Witte et al., 2011), however more recently mixed endogenous cytokines have been delivered 73 
                                                             
1
 See: Firing of Horses: RCVS position unchanged on this unethical procedure, In: RCVS 
News.  https://www.rcvs.org.uk/publications/rcvs-news-november-2011/ (Accessed 8 August 
2016) 
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in the form of platelet rich plasma (PRP, Schnabel et al., 2007; Arguelles et al., 2008; Bosch 74 
et al., 2010; McIlwraith, 2012) or stem cells (Smith et al., 2003; Smith and Webbon, 2005). 75 
Intra-lesional mesenchymal stem cell therapy yielded reduced re-injury rates in National 76 
Hunt racehorses (Godwin et al., 2012) and foetal-derived embryonic- and induced pluripotent 77 
stem cells show similar promise (Watts et al., 2011; McIlwraith, 2012; Smith et al., 2014). 78 
 79 
In spite of the evolution of tendon therapies, controlled exercise remains fundamental 80 
to the rehabilitation of SDF injuries. A standard 48-week rehabilitation program, with 81 
progress monitored ultrasonographically at 3-month intervals has been advocated (Avella and 82 
Smith, 2012; Smith and McIlwraith, 2012). 83 
 84 
Measures to quantify racehorse performance include race starts (Parente et al., 2008), 85 
races placed (Weller et al., 2006), race earnings (Cheetham et al., 2008; Parente et al., 2008), 86 
2 years post-injury racing rate (Dyson, 2004; Smith and McIlwraith, 2012), rate of 87 
completion of greater than one race (Parente et al., 2008; Smith and McIlwraith, 2012), 88 
racing post rating (RPR; Weller et al., 2006; O'Meara et al., 2010), official rating (Weller et 89 
al., 2006), and top speed rating (Weller et al., 2006). Combinations of these parameters have 90 
been used to calculate performance indices (Woodie et al., 2005; Reardon et al., 2012). 91 
Completion of five post-injury races is considered an adequate measure of success (O'Meara 92 
et al., 2010; Smith and McIlwraith, 2012). 93 
 94 
Racing outcomes have been evaluated for individual treatments, but never across 95 
multiple treatments within a population of horses from the same breed engaged in the same 96 
athletic pursuit. Randomised, masked controlled trials represent the best form of evidence for 97 
clinical decision-making, but are lacking for tendon treatments. Observational studies or 98 
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single treatment prospective studies therefore currently represent the best available evidence. 99 
This observational case-control study compared racing outcomes in a population of National 100 
Hunt racehorses in the Republic of Ireland. Outcomes were compared between injured horses 101 
and control horses, and between treatments, for a range of contemporary and more traditional 102 
therapies including thermocautery, which is still widely practised in spite of the ethical 103 
considerations. We hypothesised that lesion severity would be correlated with racing 104 
performance post-injury; that horses treated with PRP would more frequently return to 105 
racing, and at a higher standard than horses treated by bar firing, controlled exercise, tendon 106 
splitting or bar firing combined with tendon splitting; and that bar firing alone or in 107 
conjunction with tendon splitting would provide no additional benefit for racing performance 108 
post-injury. 109 
 110 
Materials and methods 111 
Horses  112 
All National Hunt racehorses that had competed over jumps under rules and were 113 
presented to a single clinic between June 2007 and July 2011 for evaluation of an SDF 114 
tendon injury were identified (Fig. 1). Two age- and sex-matched horses were selected using 115 
a random number generator from the starters of the last race prior to presentation for each 116 
injured horse, to act as controls. Where identical matches were not available, the closest 117 
matches were selected. If the treated horse had not yet raced, control horses were selected 118 
from the first race after treatment. 119 
 120 
Age, sex, horse origin (ex-store, ex-flat or point-to-point), lesion severity and 121 
treatment were taken from hospital records. Lesions were defined ultrasonographically as 122 
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mild, moderate or severe (<10%, 10-40% or >40% of tendon cross-sectional area affected at 123 
the zone of maximum injury; Smith and McIlwraith, 2012). 124 
 125 
In the acute stage, when heat, pain or swelling were evident (Smith and McIlwraith, 126 
2012), horses were box-rested and treated with non-steroidal anti-inflammatory drugs, ice 127 
and bandaging. Horses were re-evaluated during the sub-acute phase (2-3 weeks post-injury), 128 
treated as described below and/or issued a standard rehabilitation regimen. Treatment 129 
decisions were made after discussion with the trainer, rather than through random allocation. 130 
 131 
Controlled exercise  132 
A 48-week controlled exercise program was recommended, with increasing exercise 133 
intensity starting with walking only, then trotting and finally canter and fast work (Table 1).  134 
 135 
Bar firing  136 
This was undertaken under sedation with detomidine (0.01 mg/kg IV) and 137 
butorphanol (0.01 mg/kg IV). Procaine penicillin (22000 IU/kg IM), gentamycin (6.6 mg/kg 138 
IV) and phenylbutazone (4.4 mg/kg IV) were administered pre-operatively. High 4-point 139 
regional anaesthesia and proximal cannon-bone ring block were performed on the affected 140 
leg.  Horizontal lines were scored at an interval of approximately 2 cm in the skin overlying 141 
the palmar metacarpus. The glowing wire was placed against the skin, scalding the skin 142 
superficially but taking care not to cause a full thickness skin defect. A bandage was applied 143 
and changed every 48 h for 2 weeks. Horses received phenylbutazone (2.2 mg /kg PO twice 144 
daily for 7 days). The standard 48-week exercise program was recommended (Table 1).  145 
 146 
Injection of platelet rich plasma   147 
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PRP was injected 2-3 weeks after injury. PRP was harvested using an Osteokine PRP 148 
device (Dechra) and activated with calcium chloride prior to injection. Twenty-two to 25 149 
gauge needles were placed throughout the length of the lesion under ultrasound guidance. 150 
PRP was injected starting distally and proceeding proximally with final injection volume 151 
determined by lesion size. A bandage was applied and changed every 48 h for 2 weeks. 152 
Horses received phenylbutazone (4.4 mg /kg PO twice daily for 5 days) and procaine 153 
penicillin (22000 IU/kg IM twice daily for 4 days), were box rested for 2 weeks and then the 154 
standard 48-week exercise program was recommended (Table 1). 155 
 156 
Tendon splitting  157 
Horses underwent tendon splitting 3-4 weeks after injury. This was undertaken under 158 
sedation with detomidine (0.01 mg/kg IV) and butorphanol (0.01 mg/kg IV). Procaine 159 
penicillin (22000 IU/kg IM), gentamycin (6.6 mg/kg IV) and phenylbutazone (4.4 mg/kg IV) 160 
were administered pre-operatively. High 4-point regional anaesthesia and proximal cannon-161 
bone ring block were performed on the affected leg. Under ultrasound guidance a No. 11 162 
scalpel blade was introduced in a longitudinal plain into the core lesion. Repeat incisions 163 
were made over the length of the lesion. A bandage was applied and changed every 48 h for 2 164 
weeks. Horses received phenylbutazone (2.2 mg /kg PO twice daily for 7 days), were box 165 
rested for 2 weeks and then the standard 48-week exercise program was recommended (Table 166 
1). 167 
 168 
Tendon splitting then bar firing  169 
Horses underwent tendon splitting 3-4 weeks after injury using the technique 170 
described above. They subsequently underwent bar firing as described above. The interval 171 
between splitting and firing was not available for analysis.  172 
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 173 
Retired  174 
Horses were retired without further treatment for various reasons including lesion 175 
severity, financial concerns, concomitant injuries and trainer preference. 176 
 177 
Racing data collection  178 
The following racing data were obtained from the Racing Post
2
: total number of pre- 179 
and post-injury races, binary variables of completion of one, three and five races; pre- and 180 
post-injury total distance raced in furlongs; pre- and post-injury maximum RPR (RPRmax). 181 
RPR is a handicap rating determined by a horse's performance in a given race taking into 182 
account weight carried, race class and outcome. Precisely how this rating is calculated is 183 
commercially confidential. Interval (days) to the first race post-injury was compared between 184 
injured and control horses and between treatments, as were minimum, median and maximum 185 
intervals between all races post-injury. 186 
 187 
Data analysis 188 
Data were analysed using R 3.2.4 (R-Project
3
). Percentage and median (minimum and 189 
maximum) were used to summarise categorical and continuous variables. All continuous 190 
racing measurements were log transformed prior to inferential data analysis except for pre- 191 
and post-injury maximum RPR. Horses that were retired were excluded for analysis of post-192 
injury racing performance, along with their matched controls. Conditional logistic regression 193 
that accounted for the age-sex matching stratum was used to assess whether horse origin and 194 
pre-injury racing measurements were predictors of injured/control status. Linear models that 195 
                                                             
2
 See: The Racing Post: http://www.racingpost.com/ (Accessed 8 August 2016) 
3
 See: The Comprehensive R Archive Network: http://cran.r-project.org/ (Accessed 8 August 
2016) 
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adjusted for age and sex of the horses were used to assess the effect of SDF/control status on 196 
continuous post-injury racing performance. Binary logistic regression that adjusted for age 197 
and sex was used to assess the effect of injured/control status on dichotomised post-injury 198 
race measurements. Odds ratios (OR) and 95% confidence intervals (CI) from conditional 199 
logistic regression and binary logistic regression models are presented. For injured horses, 200 
Fisher’s exact tests were used to assess association between categorical variables. One-way 201 
ANOVA was used to compare continuous variables between treatment groups or severity 202 
groups. Type I error rate was set at 5%. 203 
 204 
Results 205 
Horses 206 
Three hundred and eighty-one horses were included in the study, 127 with SDF 207 
tendonitis and 254 control horses. Ex-flat racehorses made up 19% (n = 71) of the population, 208 
75% (n = 287) were ex-store horses and the remaining 6% (n = 21) were point-to-point 209 
horses (Table 2). The likelihood of injured horses being ex-flat was significantly lower than 210 
their being ex-store (OR [95% CI]: 0.398 [0.181, 0.877]; P = 0.022), but there was no 211 
difference between point-to-point and ex-store groups (1.378 [0.516, 3.682]; P = 0.523; Table 212 
2) and only a marginal difference between point-to-point and ex-flat groups (3.463 [0.990, 213 
12.112]; P=0.052). 214 
 215 
Geldings represented 82% (n = 104) of the injured horses. The remainder were mares, 216 
and sex was not correlated with horse origin (P = 0.363). Injured horses ranged in age from 217 
3-11 years (median = 6), and age was not correlated with horse origin (P = 0.799). 218 
 219 
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The number of races prior to the injury date was not correlated with injured or control 220 
status (P = 0.094; Table 2). Median pre-injury total race distance and median pre-injury 221 
RPRmax were not correlated with injured or control status (Table 2). 222 
 223 
Nine horses were retired from racing. Post-injury racing performance was analysed 224 
for the remaining 118 horses. Overall, compared to control horses, injured horses had fewer 225 
races, a shorter total distance and lower RPRmax (Table 2) post-injury. The odds of racing 226 
once (OR 0.04 [0.01, 0.15]; P < 0.001), three (0.25 [0.15, 0.41]; P < 0.001) or five (0.29 227 
[0.18, 0.46]; P < 0.001) times post-injury were also lower. Interval to first post-injury race 228 
was longer for injured horses than control horses (P < 0.001; Table 2). Median and minimum 229 
intervals between post-injury races did not differ significantly between injured horses and 230 
control horses (P = 0.246, 0.108, respectively; Table 2), but maximum interval was 231 
significantly shorter in injured horses (P < 0.001; Table 2). The timing of the largest interval 232 
between races was interval 1 in injured horses and interval 4 in control horses (P < 0.001), 233 
 234 
Lesion severity  235 
Seventeen horses (13.4%) had mild lesions, 78 (61.4%) had moderate lesions and 32 236 
(25.2%) had severe lesions. Lesion severity was not associated with horse origin (P = 0.496), 237 
sex (P = 0.530) or age (P = 0.912), nor did it have a significant correlation with pre-injury 238 
number of races (P = 0.338), pre-injury total race distance (P = 0.281) or median pre-injury 239 
RPRmax (P = 0.972; Table 6). 240 
 241 
Treatment and racing performance  242 
Treatment group was not associated with horse origin (P = 0.158; Table 3), age (P = 243 
0.298) or sex (P = 0.152), but was significantly associated with lesion severity (P < 0.001; 244 
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Table 3). Treatment group was not associated with pre-injury total race distance (P = 0.634), 245 
number of pre-injury races (P = 0.384), or with pre-injury RPRmax (P = 0.107; Table 4). Post-246 
injury number of races and total race distance did not differ with lesion severity (P = 0.593 247 
and P = 0.811, respectively; Table 6) or by treatment group (P = 0.480 and P = 0.480, 248 
respectively; Table 4). Post-injury RPRmax   did not differ with lesion severity (P = 0.635; 249 
Table 6). Overall post-injury rate of return to racing did not differ significantly by lesion 250 
severity (P = 0.650; Table 7) or treatment group (P = 0.579; Table 5). Odds of racing three 251 
times post-injury did not differ with lesion severity (P = 0.684, Table 7) or treatment group 252 
(P = 0.068; Table 5). Odds of racing five times post-injury did not differ with lesion severity 253 
(P = 0.765; Table 7) or treatment group (P = 0.730; Table 5). 254 
 255 
Interval to first post-injury race did not differ with lesion severity (P = 0.918; Table 6) 256 
or treatment group (P = 0.219; Table 4). In injured horses, median, minimum and maximum 257 
intervals between post-injury races did not differ by treatment group (P = 0.560, 0.685, 258 
0.776, respectively; Table 4) or by lesion severity (P = 0.925, 0.815, 0.834, respectively; 259 
Table 6). The timing of the largest interval between races in injured horses did not differ 260 
significantly by treatment group (P = 0.822; Table 4) or by lesion severity (P = 0.288; Table 261 
6). 262 
 263 
Discussion 264 
Relevance and homogeneity of the study population was confirmed by the absence of 265 
statistically significant differences in demographics and pre-injury racing performance 266 
between injured horses and the randomly selected, matched control horses. Subclinical 267 
tendon changes with exercise and age have been identified as predisposing factors in 268 
tendonitis (Wilmink et al., 1992; Dowling et al., 2000; Smith et al., 2002; Pinchbeck et al., 269 
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2004), but while we were not able to quantify pre-injury training load or intensity, we failed 270 
to demonstrate differences in pre-injury racing history when comparing injured horses with 271 
control horses. 272 
 273 
Our data demonstrate that SDF tendonitis remains a career limiting injury (Ross et al., 274 
2011). Injured horses had shorter careers after injury, achieved a lower career RPRmax and 275 
completed a shorter total career distance compared to control horses. After the first race post-276 
rehabilitation, intervals between post-injury races were similar between injured horses and 277 
control horses, indicating that injured horses could race as frequently as their uninjured 278 
counterparts. 279 
 280 
We hypothesised that lesion severity would be correlated with racing performance 281 
post-injury. Our data confirm that horses with severe lesions had the highest rate of 282 
retirement (Table 3; Marr et al., 1993). For treated horses, there was no difference in the rate 283 
of return to racing or the number of races post-injury across lesion severity, contrasting with 284 
previous work showing a detrimental effect of lesion severity on return to work (Marr et al., 285 
1993). Injury severity also showed no significant association with post-injury RPRmax. 286 
Although increasing lesion severity increases the rate of retirement, it need not negatively 287 
affect the post-injury racing performance of treated horses. 288 
 289 
Cost and pre-injury racing standard are likely to influence treatment selection. 290 
However, when comparing pre-injury racing standard across treatment groups, we found no 291 
evidence that horses racing at a higher standard were overrepresented in any treatment group, 292 
such as more expensive intralesional PRP. 293 
 294 
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We assessed career longevity by completion of three and five races post-injury as well 295 
as total number of races. Controlled exercise alone proved superior and bar firing inferior for 296 
the proportion of horses racing three times. Treatment group did not have an effect on the 297 
proportion of horses racing five times, reflecting the significantly shorter careers of injured 298 
horses compared to control horses overall, regardless of treatment. Previous studies have 299 
established re-injury rates ranging from 16 to 53% (Marr et al., 1993; Dyson, 2004; O'Meara 300 
et al., 2010). In the absence of verbal follow-up, we evaluated time to return to racing and the 301 
intervals between post-injury races as quantitative proxies for re-injury. The absence of 302 
differences across lesion severity and treatment group suggests that the rate of re-injury prior 303 
to a return to racing and further career intervals due to re-injury were similar across groups 304 
and lesion severities. 305 
 306 
We hypothesised that horses treated with intralesional PRP would more frequently 307 
return to racing, and at a higher standard than horses treated by other means. PRP did not 308 
prove superior to other treatments. Although it has been a popular treatment for tendonitis, 309 
the evidence for the use of PRP is weak. Experimental studies have reported stronger tissue 310 
in treated tendons compared to control horses (Bosch et al., 2010; McIlwraith, 2012) and the 311 
only case-control study describes the treatment of mid-body suspensory desmitis in nine 312 
Standardbred horses which all returned to racing following a single intralesional PRP 313 
injection (Waselau et al., 2008). While our study does not provide further clinical support for 314 
these results, postulated reasons for differences in outcome include sub-optimal platelet 315 
concentration, increased leukocyte concentration, or differences in PRP activation during 316 
administration. Platelet concentration correlates with growth factor concentration and tendon 317 
matrix gene expression and elevated leukocyte numbers can increase catabolic gene 318 
expression and reduce tendon matrix gene expression (McCarrel and Fortier, 2009; Fortier, 319 
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2011; Sundman et al., 2011). Platelet concentrations achieved with the system used in our 320 
study are comparable to those described in the literature (Sundman et al., 2011; Smith et al., 321 
2014). The method of PRP activation can influence platelet derived growth factor 322 
concentration (Textor and Tablin, 2012), but calcium chloride activation as used in our study 323 
has been reported to be optimal. 324 
 325 
The proportion of horses racing at least three times post-injury was highest for those 326 
treated with a controlled exercise rehabilitation program alone, supporting previous work 327 
showing that 71% of horses with SDF tendonitis returned to racing after a controlled exercise 328 
regimen, compared to only 25% of those that were put out to pasture (Gillis, 1997). Full 329 
compliance with rehabilitation programs can be challenging, and difficult to monitor, but 330 
regular ultrasound assessment allows horse-specific rehabilitation, reducing the recurrence of 331 
tendonitis (Gillis, 1997; Smith and McIlwraith, 2012).  332 
 333 
Although recently out of favour, tendon splitting showed similar results to controlled 334 
exercise in this study. Initially thought to promote vascularisation in chronic tendonitis cases, 335 
later studies found that splitting induced excessive granulation tissue and slowed scar tissue 336 
formation (Asheim, 1967; Stromberg.B et al., 1974; Ross et al., 2011). Tendon splitting is 337 
reported to be most effective during the acute to sub-acute stage (2-3 weeks post-injury) of 338 
injury, as in this study (Dabareiner, 2000; Ross et al., 2011; Avella and Smith, 2012; Smith et 339 
al., 2014). 340 
 341 
We hypothesised that bar firing alone or in conjunction with tendon splitting would 342 
provide no additional benefit for racing performance post-injury. Supporting a long-held 343 
hypothesis, bar firing did not yield any improvement in outcome.  A lack of improvement in 344 
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tendon histology following line firing led to the conclusion that line firing should not be 345 
considered a desirable or effective treatment of acute or chronic equine tendon injury (Silver 346 
et al., 1983). Few studies have assessed the clinical value and efficacy of firing, and even 347 
though this approach has lost support on ethical grounds, it remains commonplace. This study 348 
found no evidence to suggest that the procedure of firing offers a therapeutic advantage 349 
relative to other treatments 
4
. 350 
 351 
Post-hoc power calculations indicated that more than 160 injured horses were 352 
required in each group to detect a statistical difference in completion of five races between 353 
controlled exercise (50%) and bar firing (34.2%). Furthermore, more than 2,400 injured 354 
horses were required to demonstrate equivalence with an acceptable difference of less than 355 
10% between controlled exercise and bar firing assuming 80% power and 5% type I error 356 
rate. 357 
 358 
The realities of clinical practice and the retrospective nature of our study meant that 359 
the choice of treatment for injured horses was not randomly allocated. Injured horses vary in 360 
a number of ways that may affect outcome. Although we have demonstrated where injured 361 
horses, control horses and treatment groups were similar or different across quantifiable 362 
factors such as age, sex, lesion severity and pre-injury performance, it is possible that 363 
treatment choice was related to unquantifiable human decisions based on clinical information 364 
that could have been related to the outcome. As a result of this potential source of bias, 365 
differences or similarities between treatment groups could be due to factors related to the 366 
reason that a treatment was chosen, rather than due to treatment effects. It is impossible to 367 
                                                             
4
 See: British Equine Veterinary Association position statement on thermocautery – firing of 
tendons https://www.beva.org.uk/Portals/0/Documents/Working For Change/Thermocautery 
2014 approved.pdf (Accessed 8th August 2016) 
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compensate for these inexplicit factors in an observational study. The large sample size 368 
required in a controlled trial to demonstrate equivalence would be unlikely to be achieved 369 
given the incidence rate of SDF tendonitis and the number of horses participating in National 370 
Hunt racing in the Republic of Ireland annually. In addition, a truly randomised prospective 371 
study would be difficult to undertake for SDF tendonitis, given the realities of the racing 372 
industry and clinical practice. 373 
 374 
Conclusions 375 
Controlled exercise alone offered similar post-injury racing outcomes for National 376 
Hunt racehorses with SDF tendonitis to the other treatment options examined. Bar firing 377 
provided no additional benefit. PRP was not superior to other treatments in the studied 378 
population. 379 
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Figure legend 572 
Fig. 1. Inclusion criteria for a retrospective study of outcomes of superficial digital flexor 573 
tendon injuries in National Hunt racehorses. 574 
  575 
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Table 1. Generic rehabilitation program recommended for superficial digital flexor tendon 576 
injury in racehorses (Smith and McIlwraith, 2012) 577 
Weeks after injury Duration and nature of exercise 
1-2 Box rest 
3-4 10 min walking 
5-6 15 min walking 
7-8 20 min walking 
9-10 25 min walking 
11-12 30 min walking 
13-14 35 min walking 
15-16 40 min walking 
17-20 40 min walking; 5 min trotting 
21-24 35 min walking; 10 min trotting 
25-28 30 min walking; 15 min trotting 
29-32 45 min exercise daily with slow canter 
33-40 45 min daily with fast work three times a week 
41-48 Return to full competition/race training 
 578 
  579 
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Table 2. Horse origin, pre- and post-injury maximum racing post rating (RPRmax), number of 580 
races and race distance, post-injury inter-race intervals (range) and rate of return to racing for 581 
127 National Hunt racehorses treated for superficial digital flexor tendonitis and 254 matched 582 
control horses.  583 
 Injured horses 
a
 Control horses 
a
 P 
b
 
Total 127 254  
Horse origin    
Ex-flat 17 (13.4%) 54 (21.3%)  
Ex-store 101 (79.5%) 186 (73.2%)  
Point-to-point 9 (7.1%) 14 (5.5%) 0.043 
    
Pre-injury RPRmax 105 (0, 171) 106 (0, 170) 0.231 
Post-injury RPRmax 95 (0, 163) 113 (0, 165) <0.001 
Pre-injury races 7 (0, 66) 8 (0, 61) 0.094 
Post-injury races 3 (0, 30) 9 (0, 61) <0.001 
Pre-injury race distance (furlongs) 135 (0, 916) 138 (0, 1334) 0.204 
Post-injury race distance (furlongs) 71 (0, 621) 180 (0, 1525) <0.001 
    
Days from injury to first race 552 (152, 
1384) 
33 (1, 1090) <0.001 
Median interval between post-injury races (days) 26 (12, 384) 28 (7, 799) 0.246 
Minimum interval between post-injury races (days) 12 (1, 56) 9 (1, 799) 0.108 
Maximum interval between post-injury races (days) 151 (14, 1138) 245 (15, 1441) <0.001 
Timing of maximum interval between races (race 
number since injury) 
1 (1, 21) 4 (1, 61) <0.001 
    
Return to racing 
92/118 (78.0%) 
233/236 
(98.7%) 
<0.001 
Three races completed 
66/118 (55.9%) 
196/236 
(83.1%) 
<0.001 
Five races completed 
50/118 (42.4%) 
168/236 
(71.2%) 
<0.001 
a 
Values shown are median (range) or proportion (%) as appropriate.  584 
b 
P-values were determined by Fisher’s exact test (categorical variables) or one-way ANOVA 585 
(continuous variables).  586 
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Table 3. Horse origin and lesion severity with vertical (within treatment) and horizontal (between treatment) percentages, for 127 National Hunt 587 
horses with superficial digital flexor tendonitis. P-values were determined by Fisher’s exact test. 588 
 Treatment  
 
Controlled  
exercise 
Bar  
firing 
PRP 
Tendon  
splitting 
Tendon splitting  
and bar firing 
Retired P 
Total 24 18.9% 38 29.9% 26 20.5% 18 14.2% 12 9.4% 9 7.1%  
Horse origin  
Ex-flat  horse 
3 17.6% 3 17.6% 4 23.5% 4 23.5% 3 17.6% 0 0.0%  
12.5%  7.9%  15.4%  22.2%  25.0%  0.0%   
Ex-store horse 
21 20.8% 31 30.7% 22 21.8% 12 11.9% 8 7.9% 7 6.9%  
87.5%  81.6%  84.6%  66.7%  66.7%  77.8%   
Point-to Point 
0 0.0% 4 44.4% 0 0.0% 2 22.2% 1 11.1% 2 22.2%  
0.0%  10.5%  0.0%  11.1%  8.3%  22.2%  0.158 
Lesion Severity  
Mild 
9 52.9% 6 35.3% 2 11.8% 0 0.0% 0 0.0% 0 0.0%  
37.5%  15.8%  7.7%  0.0%  0.0%  0.0%   
Moderate 
12 15.4% 21 26.9% 20 25.6% 12 15.4% 11 14.1% 2 2.6%  
50.0%  55.3%  76.9%  66.7%  91.7%  22.2%   
Severe 
3 9.4% 11 34.4% 4 12.5% 6 18.8% 1 3.1% 7 21.9%  
12.5%   28.9%   15.4%   33.3%   8.3%   77.8%   <0.001 
PRP, intralesional platelet-rich plasma
 
589 
a
 P values were determined by Fisher’s exact test   590 
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Table 4. Pre- and post-injury maximum racing post rating (RPRmax), number of races, race distance, and post-injury inter-race intervals, for 127 591 
National Hunt horses with superficial digital flexor tendonitis. 592 
PRP, intralesional platelet-rich plasma 593 
a 
Values shown are median (range). 594 
b
 P values were determined by one-way ANOVA. Except for pre- and post-injury RPR, all variables were log transformed prior to one-way 595 
ANOVA. 
 
596 
 Treatment 
 a
  
 
Controlled  
exercise 
Bar  
firing 
PRP 
Tendon  
splitting 
Tendon 
splitting  
and bar firing 
Retired P 
 b
 
Pre-injury RPRmax 
104 (0, 171) 106 (0, 149) 112 (0, 156) 101 (58, 141) 112 (80, 132) 81 (14, 
114) 
0.107 
Post-injury RPRmax 105 (0, 163) 86 (0, 149) 95 (0, 159) 91 (0, 138) 99 (0, 150)  0.540 
Pre-injury races 7 (1, 32) 6 (0, 35) 7 (0, 42) 9 (1, 66) 6 (1, 20) 5 (1,15) 0.384 
Post-injury races 5 (0, 17) 2 (0, 22) 4 (0, 30) 5 (0, 22) 3 (0, 19)  0.480 
Pre-injury race distance (furlongs) 
135 (0, 570) 128 (0, 725) 144 (0, 677) 209 (16, 916) 96 (13, 275) 98 (24, 
277) 
0.634 
Post-injury race distance (furlongs) 102 (0, 341) 45 (0, 459) 69 (0, 621) 100 (0, 351) 77 (0, 376)  0.480 
Days from injury to first race 
513 (226, 
824) 
528 (152, 
1202) 
539 (256, 
1148) 
584 (325, 
1384) 
737 (267, 
1188) 
 0.219 
Median interval between  
post-injury races (days) 
23 (12, 68) 28 (14, 384) 25 (14, 46) 25 (15, 304) 30 (21, 39)  0.560 
Minimum interval between  
post-injury races (days) 
9 (3, 39) 14 (1, 47) 14 (2, 25) 13 (1, 56) 10 (5, 30)  0.685 
Maximum interval between  
post-injury races (days) 
118 (41, 763) 154 (14, 
731) 
91 (15, 535) 179 (25, 
1138) 
204 (30, 385)  0.776 
Timing of maximum interval between races (race 
number since injury) 
2 (1, 8) 1 (1, 18) 2 (1, 21) 2 (1, 11) 2 (1, 11)  0.822 
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Table 5. Rate of return to racing by treatment group, with vertical (within treatment) and horizontal (between treatment) percentages, for 127 597 
National Hunt horses with superficial digital flexor tendonitis. 598 
 Treatment  
 
Controlled 
exercise 
Bar 
firing 
PRP 
Tendon 
splitting 
Tendon splitting 
and bar firing 
Retired P 
a
 
Total 24 18.9% 38 29.9% 26 20.5% 18 14.2% 12 9.4% 9 7.1%  
Return to racing 
21 22.8% 28 30.4% 20 21.7% 15 16.3% 8 8.7%   0.579 
87.5%  73.7%  76.9%  83.3%  66.7%     
Three races completed 
18 27.3% 15 22.7% 15 22.7% 12 18.2% 6 9.1%     0.068 
75.0%  39.5%  57.7%  66.7%  50.0%     
Five races completed 
12 24.0% 13 26.0% 11 22.0% 9 18.0% 5 10.0%   0.730 
50.0%  34.2%  42.3%  50.0%  41.7%     
PRP, intralesional platelet-rich plasma
 599 
a
 P values were determined by Fisher’s exact test   600 
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Table 6. Pre- and post-injury maximum racing post rating (RPRmax), number of races and race distance and post-injury inter-race intervals for 601 
118 National Hunt racehorses that underwent treatment for superficial digital flexor tendonitis. This table excludes horses that were retired.  602 
 Lesion severity 
a
 
P 
b
 
 Mild Moderate Severe 
Pre-injury RPRmax 110 (0, 171) 106 (0,160) 103 (13,149) 0.972 
Post-injury RPRmax 106 (0,163) 96 (0,154) 86 (0,150) 0.635 
Pre-injury races 5 (0, 30) 7 (0, 42) 6 (1, 66) 0.338 
Post-injury races 4 (0, 19) 4 (0, 30) 3 (0, 19) 0.588 
Pre-injury race distance (furlongs) 96 (0, 570) 150 (0, 677) 135 (24, 916) 0.811 
Post-injury race distance (furlongs) 93 (0, 401) 72 (0, 621) 61 (0, 384) 0.690 
Days from injury to first race 610 (226, 812) 543 (152, 1384) 508 (281, 1202) 0.918 
Median interval between post-injury races (days) 24 (16, 68) 28 (12, 384) 25 (14, 304) 0.925 
Minimum interval between  
post-injury races (days) 
10 (3, 27) 13 (1, 56) 11 (1, 36) 0.815 
Maximum interval between  
post-injury races (days) 
179 (24, 415) 143 (15, 1138) 167 (14, 763) 0.834 
Timing of maximum interval between races (race number since injury) 1 (1, 13) 2 (1, 21) 1 (1, 11) 0.288 
a
 Values shown are median (range).  603 
b
 P-values were determined by one-way ANOVA. Except for pre- and post-injury RPR, all race variables were log transformed prior to one-way 604 
ANOVA.605 
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Table 7. Rate of return to racing by lesion severity, with vertical (within severity) and 606 
horizontal (between severity) percentages, for 118 National Hunt racehorses that underwent 607 
treatment for superficial digital flexor tendonitis. This table excludes horses that were 608 
retired.  609 
  Lesion severity 
P 
a
 
 Total Mild Moderate Severe 
Total  17  76  25   
Return to racing 92 13 14.1% 61 66.3% 18 19.6% 0.650 
  76.5%  80.3%  72.0%   
Three races completed 66 10 15.2% 44 66.7% 12 18.2% 0.684 
  58.8%  57.9%  48.0%   
Five races completed 50 7 14.0% 34 68.0% 9 18.0% 0.765 
  41.1%  44.7%  36.0%   
a  
P-values were determined by Fisher’s exact test.610 
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Figure 1. 611 
 612 
 613 
Presented with SDF tendonitis; n=244  
Horses with a full clinical history that also underwent a full evaluation were included 
in the study; n=127 
SDF tendonitis but 
missing clinical data; 
n=51 
No significant findings 
on ultrasound scan; n=9 
Bilateral tendon lesion; 
n=14 
Inciting cause was 
trauma; n=6 
Race records unavailable; 
n=7 
Concurrent problems; 
n=26 
Treatment combinations 
outside of outlined 
categories; n=4 
Page 30 of 30
